A
14.85
0.39 (2.70%)
| Previous Close | 14.46 |
| Open | 14.59 |
| Volume | 64,336 |
| Avg. Volume (3M) | 72,759 |
| Market Cap | 212,969,792 |
| Price / Earnings (Forward) | 50.00 |
| Price / Sales | 1.90 |
| Price / Book | 1.43 |
| 52 Weeks Range | |
| Earnings Date | 9 May 2025 |
| Profit Margin | -47.02% |
| Operating Margin (TTM) | -0.33% |
| Diluted EPS (TTM) | -0.600 |
| Quarterly Revenue Growth (YOY) | -28.80% |
| Total Debt/Equity (MRQ) | 16.84% |
| Current Ratio (MRQ) | 4.88 |
| Operating Cash Flow (TTM) | 5.40 M |
| Levered Free Cash Flow (TTM) | 37.84 M |
| Return on Assets (TTM) | -1.19% |
| Return on Equity (TTM) | -4.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Anika Therapeutics Inc. | Bearish | Bearish |
AIStockmoo Score
1.1
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.13 |
|
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Core |
| % Held by Insiders | 3.97% |
| % Held by Institutions | 89.79% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Alta Fundamental Advisers Llc | 31 Dec 2024 | 700,432 |
| Capital Management Corp /Va | 31 Dec 2024 | 325,545 |
| 52 Weeks Range | ||
| Median | 20.00 (34.68%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barrington Research | 13 Mar 2025 | 20.00 (34.68%) | Buy | 15.21 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 09 May 2025 | Announcement | Anika Reports First Quarter 2025 Financial Results |
| 25 Apr 2025 | Announcement | Anika to Issue First Quarter 2025 Financial Results on Friday, May 9, 2025 |
| 07 Apr 2025 | Announcement | Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 12 Mar 2025 | Announcement | Anika Reports Fourth Quarter and Full Year 2024 Financial Results |
| 07 Mar 2025 | Announcement | Anika Completes Divestiture of Parcus Medical |
| 26 Feb 2025 | Announcement | Anika to Issue Fourth Quarter and Year-End 2024 Financial Results on Wednesday, March 12, 2025 |
| 25 Feb 2025 | Announcement | Anika To Present at the Canaccord Genuity 2025 Musculoskeletal Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |